Research Square
September 25, 2025
David Greguš, Jaroslav Hlinka, Filip Tylš et al.
preprint
Abstract Rationale: Individual variability in psilocybin response is a major challenge for psychedelic-assisted therapy, with structural brain features potentially serving as predictive biomarkers. Lewis et al. (2020) reported that rostral anterior cingulate cortex thickness predicted emotional experiences under psilocybin, suggesting cortical morphometry as a marker of psychedelic...
Behavioural Pharmacology
September 25, 2025
Saadet Inan, Paige E. Morris, Scott M. Rawls et al.
Psilocybin is found in a family of mushrooms commonly known as Psilocybe. We aimed to study the antinociceptive efficacy of psilocybin using formalin-induced noxious stimuli, a model that comprises both acute and persistent pain in rats. Adult male Sprague–Dawley rats were used. Psilocybin (0.1, 0.3, and 1 mg/kg, IP) or vehicle was administered, and 6 h later, formalin (5%, 50 µL, subcutaneous)...
Progress in Neuro-Psychopharmacology and Biological Psychiatry
September 24, 2025
Marie Celine Dorczok, Gloria Mittmann, Thomas Ettl et al.
2 citations
PAP combined with structured psychological support shows sustained reductions in depressive symptoms for treatment-resistant depression and major depressive disorder. Higher doses generally yield stronger benefits. While PAP holds significant potential as a holistic treatment, methodological limitations, such as heterogeneity in study designs, inconsistent levels of psychological support and...
EClinicalMedicine
September 24, 2025
Megan Hosein, Matthew J Reid, Sarah A. Walser et al.
5 citations
The potential for psilocybin, and other psychedelic drugs, to fulfil a much needed and potentially transformative class of psychiatric treatments has garnered significant attention. Consequently, there has been a great deal of interest and investment in accelerating its development and potential implementation in routine clinical practice. However, the expanding scope of scientific discovery,...
Journal of Psychopharmacology
September 22, 2025
Vítor Bruno, Martha López-canul, Brandon Richardson et al.
3 citations
Background: In recent years, there has been a resurgence of scientific interest in psychedelics, including psilocybin, for their potential in treating neuropsychiatric disorders. However, the reward-related effects of psilocybin and its impact on behavior remain underexplored. Aims: We aimed to evaluate the potential rewarding effects of high doses of psilocybin and its effects on rat behavior....
Angewandte Chemie
September 21, 2025
Tim Schäfer, Fabian Haun, Bernhard Rupp et al.
Zusammenfassung Psilocybin (4‐Phosphoryloxy‐ N , N ‐dimethyltryptamin, 1 ) ist der hauptsächliche Indolethylamin‐Naturstoff der psychotropen sogenannten Zauberpilze. Die Mehrheit der 1 ‐produzierenden Arten gehört zu der namensgebenden Gattung Psilocybe , für die die biosynthetischen Ereignisse, ausgehend von l ‐Tryptophan ( 2 ), sowie die beteiligten Enzyme gründlich charakterisiert wurden....
Angewandte Chemie International Edition
September 21, 2025
Tim Schäfer, Fabian Haun, Bernhard Rupp et al.
7 citations
Abstract Psilocybin (4‐phosphoryloxy‐ N , N ‐dimethyltryptamine, 1 ) is the main indolethyl‐amine natural product of psychotropic (so‐called “magic”) mushrooms. The majority of 1 ‐producing species belongs to the eponymous genus Psilocybe , for which the biosynthetic events, beginning from l ‐tryptophan ( 2 ), and the involved enzymes have thoroughly been characterized. Some Inocybe (fiber cap)...
Addiction
September 20, 2025
Elizabeth Knock, Krista J. Siefried, Gillinder Bedi et al.
4 citations
Abstract Background & Aims There are few effective treatments for methamphetamine use disorder, despite increasing global demand. Here, we assessed the safety and feasibility of outpatient psilocybin‐assisted psychotherapy for methamphetamine use disorder. Design Single arm, open label pilot study. Setting Outpatient public stimulant treatment program at St. Vincent's Hospital, Sydney,...
OPAL (Open@LaTrobe) (La Trobe University)
September 19, 2025
Supplement 1. Additional tables presenting primary and secondary outcomes, sensitivity analyses, and exploratory findings. Table A1. ITT analyses for QIDS-SR-16 and MBI-HSS-MP. Table A2. Adjusted ITT analyses for QIDS-SR-16 and MBI-HSS-MP. Table B1. Intent-To-Treat (ITT) Analysis for Demoralization Scale (DSII) and PTSD Checklist for DSM-5 (PCL-5). Table B2. Adjusted Intent-To-Treat (ITT)...
PLoS Medicine
September 19, 2025
Benjamin R. Lewis, John Hendrick, Kevin Byrne et al.
5 citations
Background Depression and burnout, which are common among healthcare workers, were exacerbated by the COVID-19 pandemic. Mindfulness-Based Stress Reduction (MBSR) and psilocybin have been reported to reduce depressive symptoms, but the efficacy of the combination requires comparison to an active treatment control. We sought to evaluate the safety and preliminary efficacy of psilocybin and MBSR...